Estudo randomizado | Ripretinibe vs. sunitinibe em pacientes com tumor estromal gastrintestinal avançado após tratamento com imatinibe.

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Editorial: Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine – Journal of Clinical Oncology

Comentário no Twitter

👀 INTRIGUE Trial: Ipretinib not superior to sunitinib but demonstrates longest median progression free survival ever in advanced #GastrointestinalStromalTumor ➡️ https://t.co/aUNdvXaQcH #GIST #scmsm @seppobauer pic.twitter.com/pPfph6A8Lr

— Journal of Clinical Oncology (@JCO_ASCO) August 24, 2022